Industry Outlook
Businesswire | July 21, 2023
Sangamo Therapeutics, Inc. a clinical-stage genomic medicine company and Chroma Medicine, Inc. a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deploying them to address numerous therapeutically relevant targets. Advancing the transformative potential of epigenetic editing, Chroma is expanding the versatility of its platform by leveraging Sangamo’s ZFPs. Following a research evaluation period, Chroma has the option to license the ZFPs for potential worldwide development and commercialization of epigenetic medicines for certain therapeutic targets.
“Sangamo is the world leader in zinc finger protein genomic engineering, and we are very proud of the range and depth of our capabilities in this area,” said Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo. “We believe our ability to rapidly design and engineer highly potent and specific ZFPs can provide unique and highly valuable capability beyond what is available with competing technologies. We are constantly seeking to deploy our technology with partners outside of our core neurology focus area and are very happy to explore combining our ZF technology with Chroma’s unique capabilities. We believe that this work will further validate the importance of zinc fingers as an ideal platform to support epigenetic editing.”
Under the terms of the agreement, Chroma will evaluate novel Sangamo ZFPs for specified collaboration targets outside of the central nervous system in exchange for an upfront technology access payment. If Chroma exercises its option for any or all targets, Sangamo would be eligible to receive an option exercise payment, in addition to potential development and commercial milestone payments, as well as royalties on any Chroma products incorporating the licensed ZFPs. Chroma will lead and fund all research, development, manufacture, and commercialization of products incorporating the licensed Sangamo ZFPs.
“As a leader in epigenetic editing, Chroma has advanced and optimized our platform, showing highly efficient, specific, and durable gene silencing in vivo and the ability to accomplish multiplex epigenetic editing without induction of indels or chromosomal rearrangements,” said Vic Myer, Ph.D., President and Chief Scientific Officer of Chroma. “Leveraging Sangamo’s leading zinc finger protein engineering capabilities expands our platform optionality, further positioning Chroma to progress a broad portfolio of epigenetic editing therapeutics that spans several indications.”
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist.
About Chroma Medicine, Inc.
Chroma Medicine is a biotechnology company pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company was founded by the world’s foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development.
Read More
Medical, Industry Outlook
PRNewswire | July 12, 2023
Anbio, a leading provider of innovative diagnostic solutions, proudly presents the Anbio ADL i1910, a fully automated, compact, and affordable CLIA analyzer designed to transform the landscape of clinical diagnostics. With its cutting-edge technology and versatile capabilities, the ADL i1910 offers a comprehensive range of qualitative and quantitative testing options for analytes in human serum, plasma, whole blood, and urine samples.
The ADL i1910 utilizes a direct chemiluminescence method based on acridinium ester, ensuring accurate and reliable results across a wide array of applications. Whether it's hormone detection, myocardial disease screening, infectious disease diagnostics, or tumor-related antigen analysis, the ADL i1910 delivers exceptional performance and meets the diverse needs of modern healthcare professionals.
Key Features of the Anbio ADL i1910
Extensive Assay Menu: The ADL i1910 boasts an impressive range of 49 developed assays, allowing for both qualitative and quantitative testing of analytes. This comprehensive immunodiagnostic solution enables healthcare providers to access critical information efficiently.
High Throughput: With a remarkable throughput of up to 120 tests per hour, the ADL i1910 significantly enhances laboratory productivity. Rapid turnaround times enable healthcare providers to make timely and informed decisions, ultimately improving patient care.
Compact Footprint: Anbio understands the importance of laboratory space. The ADL i1910 has been meticulously designed to occupy minimal space, making it suitable for laboratories of all sizes. Its small footprint ensures that valuable space can be optimized for other essential equipment.
User-Friendly Interface: The ADL i1910 features an intuitive graphic user interface with a large color touch screen, simplifying operation and minimizing the learning curve. The user-friendly design ensures ease of use for both experienced professionals and new users, enhancing overall efficiency.
"Anbio is proud to introduce the ADL i1910, a breakthrough CLIA analyzer that revolutionizes clinical diagnostics," said Jack Davis, Chief Business Officer at Anbio. "With its advanced technology, extensive assay menu, and impressive throughput, the ADL i1910 provides healthcare professionals with a reliable and efficient solution for a wide range of diagnostic applications."
The Anbio ADL i1910 is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution.
About Anbio Biotechnology
Anbio Biotechnology is devoted to making contributions for human health and has never stopped our goal to innovate in life sciences. Driven by continuous technical development and integration, resulting from close cooperation with prestigious institutes across the world. Anbio always strives to provide total solutions in clinical diagnosis field, by offering extensive diagnostic products including laboratory and point-of-care products.
Read More
Medical
businesswire | September 26, 2023
BenevolentAI a leader in the development of advanced AI that accelerates biopharma discovery, announces that it has signed a strategic collaboration with Merck, a leading science and technology company headquartered in Darmstadt, Germany.
The collaboration will enable Merck to leverage BenevolentAI’s powerful end-to-end AI platform capabilities and gain access to an expert team of interdisciplinary drug discovery scientists with the aim of identifying and developing innovative compounds, through Hit Identification (Hit ID) to pre-clinical stage.
BenevolentAI will leverage its suite of AI chemistry design tools, in combination with its fully equipped wet lab facility in Cambridge (UK), to deliver small molecule drug development candidates into the Merck pipeline, ready for onward pre-clinical and clinical development.
Under the terms of the agreement, BenevolentAI will be eligible for payments of up to $594 million, consisting of a low double-digit million dollar upfront payment on signing and then potentially discovery, development and commercial milestones. Tiered royalties will also be payable on net sales of any commercialised products.
Joanna Shields, Chief Executive Officer of BenevolentAI, said: “Our strategic collaboration with Merck exemplifies BenevolentAI’s unique capability to leverage AI to accelerate drug discovery. Our proprietary technology and extensively validated approach of combining AI, molecular biology, medicinal chemistry, and in vivo pharmacology supports the discovery of innovative drug candidates in fewer cycles. We look forward to working with the Merck team and are excited at the opportunities in our partnership.”
Public disclosure of inside information in accordance with article 17(1) of the Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation)
About BenevolentAI
BenevolentAI is a leading developer of advanced artificial intelligence technologies that unlock the value of multimodal data, surface novel insights, and accelerate biomedical discovery. Through the combined capabilities of its AI platform, its scientific expertise, and wet-lab facilities, the Company is developing an in-house drug pipeline of high-value assets. The Company is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Read More